Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PM14 plus irinotecan in pretreated advanced solid tumors
2024-514890-24-00Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ecubectedin and irinotecan in Nonhematologic neoplasms, esophageal cancer, gastric adenocarcinoma and 23 more (2 arms), sponsored by PharmaMar. Primary endpoints: Maximum tolerated dose and recommended dose and Overall response rate. Started Aug 2024; status: completed.
02
Drugs
ecubectedinirinotecan
03
Conditions
Nonhematologic neoplasmsesophageal cancergastric adenocarcinomapancreatic adenocarcinoma (PDAC)biliary cancer
Beyond the preview
Go deeper on 2024-514890-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514890-24-00.